BPL Plasma’s Post

Thoughts on this? >> Blueprint ups Ayvakit guidance; Aurinia to advance autoimmune disease asset >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare

Join us as we dive into the phenomenon of Low Endotoxin Recovery (LER) and learn how the ENDO-RS® kit and ENDOLISA® assay play a crucial role in detecting endotoxin interference. 🧪 Download our comprehensive case study: https://lnkd.in/d95Sh_ih

Why choose CoreBioLabs as your reference laboratory? Experience a supportive partnership that enhances your diagnostic capabilities. Learn more at

Dive into the phenomenon of Low Endotoxin Recovery (LER) and learn how the ENDO-RS® kit and ENDOLISA® assay play a crucial role in detecting endotoxin interference. 🧪 Download  bioMérieux's  comprehensive case study!

Dive into the phenomenon of Low Endotoxin Recovery (LER) and learn how the ENDO-RS® kit and ENDOLISA® assay play a crucial role in detecting endotoxin interference. 🧪 Download  bioMérieux's  comprehensive case study!

Dive into the phenomenon of Low Endotoxin Recovery (LER) and learn how the ENDO-RS® kit and ENDOLISA® assay play a crucial role in detecting endotoxin interference. 🧪 Download  bioMérieux's  comprehensive case study!

Today we announced positive topline results from our Phase 1 study of DARE-PDM1, our investigational product designed to deliver diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), vaginally via our proprietary hydrogel to treat primary dysmenorrhea, or painful menstruation. At Daré, we’re committed to advancing a portfolio of differentiated product candidates that address meaningful unmet needs in women’s health. The data from this Phase 1 study, which evaluated the pharmacokinetics, safety and exploratory efficacy of DARE-PDM1, support its continued clinical development as well as its potential as a first-in-category product, delivering diclofenac in a convenient vaginal format that may extend the duration of pain relief and reduce the risks associated with the oral delivery of NSAIDs. Learn more about DARE-PDM1: https://lnkd.in/ea6h2ZiH

Rare diseases are more common than you think. Each year, #RareDiseaseDay raises awareness of rare diseases and recognizes more than 30 million U.S. patients who are affected. Despite the successes and progress towards fighting the thousands of known rare diseases which exist, there is more work to do. Biopharmaceutical researchers are dedicated to advancing medicine to help rare disease patients live long, healthy lives with more innovative treatment options in the pipeline. Learn more: https://bit.ly/3UTsXAQ

EyeBio doubles the size of its Series A as anti-VEGF veterans seek new ways of treating retinal diseases >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #biotech #productmarketing

Looking for some inspiration on this Monday? We’ve got some for you in this upcoming Webinar featuring our very own Geoff Johnson, MD, PhD. I have the privilege of interviewing Geoff for our first episode of several highlighting the importance of radiopharmaceuticals and the ongoing need for research, development, and utilization of these agents in clinical practice. #radiopharmaceuticals #prostatecancer #NucleusRadioPharma #Mayo #innovation